An Evidence-Based Review of Watch-and-Wait Strategy in Locally Advanced Rectal Cancer Achieving Complete Response After Neoadjuvant Chemoradiotherapy
To compare the clinical outcomes of the W&W strategy and surgery in locally advanced rectal cancer patients who achieved a clinical complete response (cCR) status post-neoadjuvant therapy. We searched for meta-analyses, clinical trials, and observational studies comparing two treatment strategies up to May 2023 in several databases, including PubMed, Embase, and Cochrane Library. We reported the article selection process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and appraised the studies using the Oxford Center for Evidence-Based Medicine criteria. From 164 articles, we included two meta-analyses, one clinical trial, and four observational studies that met the criteria of validity, importance, and applicability. These studies indicated that the proportion of patients adopting the W&W strategy was limited. Most studies showed that the W&W group had a higher local recurrence rate than the surgery group. However, there was no significant difference in metastasis rates, disease-free survival (DFS), and overall survival (OS). The W&W strategy could be decided upon by a multidisciplinary approach in rectal cancer patients achieving cCR status after neoadjuvant therapy. Despite the higher local recurrence rate in the W&W group, strict surveillance and salvage therapy could provide a similar outcome.
1. The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer 2020;858:1–2.
2. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023;73(3):233–54.
3. Gaertner WB, Kwaan MR, Madoff RD, Melton GB. Rectal cancer: An evidence-based update for primary care providers. World J Gastroenterol 2015;21(25):7659-71.
4. Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, et al. Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol 2019;25(33):4850–69.
5. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022. J Natl Compr Canc Netw 2022;20(10):1139–67.
6. Van De Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 2014;50(1):1.e1–1.e34.
7. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2018 clinical practice guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874–901
8. Maas M, Beets-Tan RGH, Lambregts DMJ, Lammering G, Nelemans PJ, Engelen SME, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011;29(35):4633-40.
9. Jimenez-Rodriguez RM, Quezada-Diaz F, Hameed I, Kalabin A, Patil S, Smith JJ, et al. Organ preservation in patients with rectal cancer treated with total neoadjuvant therapy. Dis Colon Rectum 2021;64(12):1463–70.
10. Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JCR, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study. Lancet Oncol 2015;16(8):919–27.
11. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva E Sousa AH, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann Surg 2004;240(4):711–8.
12. Habr-Gama A, São Julião GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: The impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg 2019;269(1):102–7.
13. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21(6):653–77.
14. Glynne-Jones R, Wallace M, Livingstone JIL, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: Is a “wait and see” policy justified? Dis Colon Rectum 2008;51(1):10–9.
15. Asoglu O, Bulut A, Aliyev V, Piozzi GN, Guven K, Bakır B, et al. Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series. World J Surg Oncol 2022;20(1):358.
16. Lee SY, Kim CH, Kim YJ, Kim HR. Oncologic outcomes according to the treatment strategy in radiologic complete responders after neoadjuvant chemoradiation for rectal cancer. Oncology Switzerland 2015;89(6):311–8.
17. Van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study. Lancet 2018;391(10139):2537–45.
18. Yu G, Lu W, Jiao Z, Qiao J, Ma S, Liu X. A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy. World J Surg Oncol 2021;19(1):305.
19. Kim HJ, Song JH, Ahn HS, Choi BH, Jeong H, Choi HS, et al. Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy. Int J Colorectal Dis 2017;32(5):723–7.
20. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022;40(23):2546–56.
21. Han Z, Li M, Chen J, Ji D, Zhan T, Peng Y, et al. Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy. Asian J Surg 2022;45(1):97–104.
22. Zhang S, Zhang R, Li RZ, Wang QX, Chang H, Ding PR, et al. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Sci 2021;112(9):3607–15.
23. Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant Therapy. JAMA Oncol 2019;5(4):e185896.
24. Yeom SS, Lee SY, Kim CH, Kim YJ, Nam TK, Kim HR. Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy. Asian J Surg 2019;42(8):823–31.
25. Millan M, Merino S, Caro A, Feliu F, Escuder J, Francesch T. Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol 2015;7(10):204–20.
26. Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhavatia S, Dalal I, et al. Management of locally advanced rectal cancer in the elderly: A critical review and algorithm. J Gastro intest Oncol 2018;9(2):363–76.
27. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49.
28. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol 2019;14(2):89–103.
29. Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, et al. Organ preservation in rectal adenocarcinoma: A phase II randomized controlled trial evaluating 3-year diseasefree survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015;15(1):767.
30. Byun HK, Koom WS. A practical review of watch-and-wait approach in rectal cancer. Radiat Oncol J 2023;41(1):4–11.